Self-Administered Medication Market’s CAGR of 6.3%: Leaders Shaping Home Care According to a newly published market research report by 24LifeSciences, global self-administered medication market was valued at USD 185.6 billion in 2026 and is projected to reach USD 285.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Self-administered medications encompass pharmaceutical products that patients can safely use without direct professional supervision, spanning various administration routes including oral tablets, subcutaneous injections, nasal sprays, and transdermal patches. This market represents a fundamental shift toward patient-centered healthcare, empowering individuals to manage chronic conditions like diabetes, rheumatoid arthritis, and hormone deficiencies conveniently at home. The growing acceptance of these therapies reflects broader trends in healthcare decentralization and patient autonomy. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8887/self-administered-medication-market

Top 10 Companies Shaping the Global Parathyroid Disorders Market (2026–2034) According to a newly published market research report by 24LifeSciences, global parathyroid disorders market is valued at USD 2.1 billion in 2026 and is projected to reach USD 3.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period. Parathyroid disorders are medical conditions resulting from the dysfunction of the parathyroid glands, four small glands located in the neck that regulate the body's calcium levels. These disorders lead to abnormal calcium levels in the blood, which can cause significant health issues such as brittle bones (osteoporosis), kidney stones, chronic fatigue, and muscle weakness. The primary disorders include hyperparathyroidism (overactive glands), hypoparathyroidism (underactive glands), and the rare parathyroid cancer. Market growth is primarily driven by an aging global population more susceptible to these conditions and the rising prevalence of chronic kidney disease (CKD), a major cause of secondary hyperparathyroidism. Furthermore, advancements in diagnostic techniques, such as more sensitive parathyroid hormone (PTH) assays, are facilitating earlier and more accurate detection. Key players like Amgen, with its calcimimetic drug Cinacalcet, and Abbott Laboratories, a leader in diagnostic solutions, are actively shaping the treatment landscape through innovation and strategic initiatives, contributing to market expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9574/parathyroid-disorders-market

Orphan Diseases Market to Reach USD 834 million by 2034 | Growth Trends & Insights According to a newly published market research report by 24LifeSciences, global orphan diseases market is valued at USD 315 million in 2026 and is projected to reach USD 834 million by 2034, growing at a compound annual growth rate (CAGR) of 15.3% during the forecast period. An orphan disease is officially defined as a condition affecting fewer than 200,000 people in the United States, encompassing a wide spectrum of disorders from more recognized conditions like cystic fibrosis and ALS (Lou Gehrig's disease) to rare genetic disorders such as Hutchinson-Gilford progeria syndrome. The vast majority of these diseases are genetic in origin, creating significant challenges and opportunities for targeted therapeutic development. These conditions represent some of the most complex medical challenges facing modern healthcare, requiring specialized approaches to both diagnosis and treatment. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9568/orphan-diseases-market

How Rapid and Molecular Diagnostics Are Shaping the Brucellosis Test Kits Market According to a newly published market research report by 24LifeSciences, global brucellosis test kits market is valued at USD 315.7 million in 2026 and is projected to reach USD 458.6 million by 2034, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period. Brucellosis test kits are in-vitro diagnostic (IVD) tools designed for the serological detection of antibodies against Brucella bacteria, a critical component in diagnosing both human and animal brucellosis. These kits play an essential role in managing this zoonotic disease, which causes significant economic losses in livestock production and poses serious public health risks. The most common formats include Brucella IgG, IgM, and IgA ELISA kits, along with traditional methods like rose bengal plate tests (RBPT) and advanced fluorescence polarization assays (FPA). Their accuracy and reliability make them indispensable for veterinary diagnostics, food safety programs, and human healthcare systems worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9628/brucellosis-test-kits-market

How Are Non-Invasive Diagnostics and Imaging Advances Fueling a 4.3% CAGR in the UV Skin Analysis Machines Market? Intel Market Research, the global UV skin analysis machines market was valued at USD 50.2 million in 2026 and is projected to reach USD 69.5 million by 2034, growing at a steady CAGR of 4.3% during the forecast period (2025-2034). This growth is driven by increasing awareness of skin health, rising demand for non-invasive diagnostic tools, and technological advancements in dermatological imaging. https://www.intelmarketresearch.com/uv-skin-machines-market-30300

How Is the Global Pet Eye Care Market Growing at a 6.2% CAGR Through 2034? Intel Market Research, the global Pet Eye Care Market was valued at USD 143 million in 2026 and is projected to reach USD 215 million by 2034, growing at a CAGR of 6.2% during the forecast period (2025-2034). This growth is fueled by rising pet ownership rates, increasing awareness about pet ocular health, and technological advancements in veterinary ophthalmology. https://www.intelmarketresearch.com/pet-eye-care-market-31066

How Will the Global Prebiotics Market Grow at a 5.3% CAGR Through 2034? Intel Market Research, the global Prebiotics market was valued at USD 154 million in 2024 and is projected to reach USD 219 million by 2034, growing at a CAGR of 5.3% during the forecast period (2026–2034). This steady growth reflects increasing consumer awareness about gut health and rising demand for functional foods with digestive benefits. https://www.intelmarketresearch.com/prebiotics-market-29097

What’s Driving a Robust 8.2% CAGR in the Global Elderly Walking Aids Market (2025–2031)? Intel Market Research, the global elderly walking aids market was valued at USD 1.62 billion in 2024 and is projected to reach USD 2.78 billion by 2031, growing at a robust CAGR of 8.2% during the forecast period (2025–2031). This growth is propelled by the aging global population, increasing healthcare expenditure on senior care, and technological advancements in lightweight materials and smart features. https://www.intelmarketresearch.com/elderly-walking-aids-market-9854

Global Generic Oncology Drugs Market Size & Growth Drivers Through 2034 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

Generic Oncology Drugs Market’s CAGR of 6.3%: Leading Companies to Watch in 2026 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

Viagra and Heart Health: Risks, Benefits, Alternatives, and More

https://m2squareconsultancy.com/reports/healthcare-biometrics-market